Top Page
BioCardia
(NASDAQ:BCDA)
BioCardia (BCDA) vs. SPDR S&P 500 ETF (SPY)
BioCardia Business Overview & Revenue Model
BioCardia Earnings Call Summary
BioCardia Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.00K | 58.00K | 477.00K | 1.35M | 1.01M | 145.00K |
| Gross Profit | -431.00K | -372.00K | 66.00K | 975.00K | 375.00K | 141.00K |
| EBITDA | -8.71M | -7.93M | -11.56M | -11.82M | -12.57M | -14.44M |
| Net Income | -8.79M | -7.95M | -11.57M | -11.91M | -12.62M | -15.00M |
Balance Sheet | ||||||
| Total Assets | 2.09M | 3.72M | 2.99M | 9.79M | 15.72M | 23.42M |
| Cash, Cash Equivalents and Short-Term Investments | 980.00K | 2.37M | 1.10M | 7.36M | 12.87M | 21.41M |
| Total Debt | 745.00K | 951.00K | 1.31M | 1.63M | 1.87M | 614.00K |
| Total Liabilities | 3.98M | 2.89M | 4.59M | 4.90M | 5.34M | 4.25M |
| Stockholders Equity | -1.89M | 837.00K | -1.60M | 4.89M | 10.38M | 19.18M |
Cash Flow | ||||||
| Free Cash Flow | -8.46M | -8.03M | -9.99M | -10.63M | -10.48M | -12.39M |
| Operating Cash Flow | -8.45M | -8.03M | -9.97M | -10.56M | -10.37M | -12.36M |
| Investing Cash Flow | -4.00K | -6.00K | -12.00K | -70.00K | -116.00K | -32.00K |
| Financing Cash Flow | 8.01M | 9.30M | 3.73M | 5.12M | 1.95M | 28.21M |
BioCardia Technical Analysis
BioCardia Risk Analysis
BioCardia Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $9.96M | ― | -81.33% | ― | -62.68% | 23.94% | |
51 Neutral | $7.95B | -0.40 | -42.50% | 2.21% | 22.29% | -1.85% | |
50 Neutral | $11.95M | ― | -737.89% | ― | -100.00% | 60.53% | |
48 Neutral | $11.26M | ― | -238.26% | ― | -57.69% | 63.76% | |
48 Neutral | $11.60M | ― | ― | ― | 48.91% | ||
| ― | $379.87M | ― | -371.02% | ― | ― | ― | |
48 Neutral | $12.76M | ― | -137.09% | ― | 247.62% | -7.66% |
BioCardia Corporate Events
On August 13, 2025, BioCardia, Inc. and CART-Tech, B.V. announced an exclusive development and commercialization agreement for Heart3D™ Fusion Imaging, aimed at enhancing cardiac biotherapeutic delivery and biopsy procedures. The system, which fuses two-dimensional x-ray images with three-dimensional anatomical heart models, is initially intended for research use and may later be approved for standard clinical practice. This partnership leverages both companies’ expertise and intellectual property, with BioCardia securing exclusive distribution rights for biotherapeutic delivery worldwide and cardiac biopsy in the U.S. The collaboration is expected to improve procedural planning and real-time image precision, potentially generating significant revenue if adopted as a standard of care.
On August 4, 2025, BioCardia, Inc. announced updates on the regulatory approval timeline for its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter. The company plans to submit a DeNovo 510(k) application for the Helix system to the FDA in Q3 2025, leveraging its safety and performance in numerous clinical studies. Additionally, BioCardia aims to discuss the approval pathway for CardiAMP Cell Therapy for ischemic heart failure with the FDA in Q4 2025, highlighting its previous Breakthrough Designation and clinical trial results. A clinical consultation with Japan’s PMDA is also expected in Q4 2025, potentially facilitating market entry in Japan. These developments could significantly impact BioCardia’s market positioning and provide new opportunities for stakeholders.
On July 24, 2025, BioCardia announced the submission of its CardiAMP autologous cell therapy for heart failure to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for clinical consultation. This submission is a crucial step towards potential regulatory approval in Japan, a significant market for advanced heart failure treatments. The consultation will involve a comprehensive review of clinical data from the CardiAMP HF trial, assessing the therapy’s efficacy, safety, and fit within the Japanese healthcare system. Successful alignment with PMDA could lead to market entry in Japan and a subsequent post-marketing study, enhancing BioCardia’s industry positioning and offering new opportunities for collaboration.
On July 16, 2025, BioCardia announced that Henry Ford Health in Detroit, Michigan, has begun enrolling patients with ischemic heart failure in the company’s pivotal Phase 3 CardiAMP HF II trial. This trial is a confirmatory study of autologous bone marrow-derived mononuclear cell therapy, aiming to promote microvascular repair and improve heart function in patients with ischemic heart failure. The trial seeks to confirm the safety and efficacy results observed in previous studies and could potentially enhance treatment options for patients with heart failure.
On June 30, 2025, BioCardia, Inc. completed a private placement agreement with institutional buyers and company insiders, raising approximately $570,000. The funds will be used for general corporate purposes, and the company plans to register the shares for resale with the SEC by July 10, 2025.
On June 25, 2025, BioCardia announced the granting of US Patent No. 12,311,127 for its ‘Radial and Trans-endocardial Delivery Catheter’ by the United States Patent Office. This patent covers BioCardia’s minimally invasive catheter systems designed to deliver biologic therapies to the heart, enhancing treatment precision and safety. The Helix catheter system, integral to the company’s CardiAMP Cell Therapy program, is expected to significantly impact the treatment of ischemic cardiomyopathies and heart failure, potentially improving patient outcomes and facilitating the transition from development to commercialization.